Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
The ruling Liberal Democratic Party’s (LDP) project team on pharmaceutical innovation formally submitted its growth strategy proposal to the health ministry on April 24, calling for maintaining drug prices during the patent period, including through a review of the cost-effectiveness…
To read the full story
Related Article
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- LDP Project Team to Seek Patent-Period Price Maintenance in Growth Strategy Proposal
April 21, 2026
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
- Council Floats 9.6% Growth Goal for Global Patented Drug Sales by Japan Pharma
March 11, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
- Executives Urge Stronger CDMO, CRO Base at Drug Discovery WG Meeting
February 27, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
- Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…